Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma

Journal of Urology

Volumn 161, Issue 3, 1999, Pages 945-949

  Myers, Russell B ^a   Oelschlager, Denise K ^a   Coan, Patricia N ^a   Frost, Andra R ^a   Weiss, Heidi L ^a   Manne, Upender ^a   Pretlow, Thomas G ^a   Grizzle, William E ^a  

^a NONE

Author keywords

Androgen; Prostatic neoplasm

Indexed keywords

ANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; TESTOSTERONE;

APOPTOSIS; ARTICLE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

EID: 0032830278     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61826-3     Document Type: Article

References (24)

1. Huggins, C. and Hodges, C. V.: Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293, 1941.
2. Schroder, F. H.: Hormonal therapy for prostate cancer. In: Prostate Diseases. Edited by H. Lepor and R. K. Lawson. Philadelphia: W. B. Saunders, pp. 347-363, 1993.
3. Kyprianou, N., English, H. F. and Issacs, J. T.: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748, 1990.
4. Gleave, M. E., Goldenberg, S. L., Jones, E. C., Bruchovsky, N. and Sullivan, L. D.: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J. Urol., 155: 213, 1996.
5. Van Steenbrugge, G. J. Hormones. In: The Nude Mouse in Oncology Research. Edited by E. Boven and B. Winograd. Boston, MA: CRC Press: pp. 216-226, 1991.
6. Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., Resnick, M. I., Seftel, A. and Pretlow, T. G.: CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049, 1994.
7. Janek, P., Briand, P. and Hartman, N. R.: The effects of estroneprogesterone treatment on cell proliferation kinetics of hormone dependent GR mouse mammary tumors. Cancer Res., 35: 3698, 1975.
8. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst., 86: 1140, 1994.
9. Hommel, G.: A stepwise rejective multiple test procedure based on a modified Bonferroni test. Biometrika, 75: 383, 1988.
10. Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H. and Sullivan, L. D.: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J. Steroid Biochem. Mol. Biol., 58: 139, 1996.
11. Sato, N., Gleave, M. E. Bruchovsky, N., Rennie, P. S., Beraldi, E. and Sullivan, L. D.: A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res., 57: 1585, 1997.
12. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H-J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B. and Pretlow, T. G.: CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042, 1996.
13. Elledge, S. J. and Harper, J. W.: CdK inhibitors: on the threshold of checkpoints and development. Current Opin. Cell Biol., 6: 847, 1994.
14. 1 phase and cell cycle regulation by TGF-β. Adv. Cancer Res., 71: 165, 1997.
15. Kip-1, a cyclin-CdK inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Develop., 8: 9, 1994.
16. Liu, X-H., Wiley, H. S. and Meikle, W.: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-α (TGF-α) and epidermal growth factor (EGF)/TGFα receptor. J. Clin. Endocrinol. Metab., 77: 1472, 1993.
17. Kyprianou, N. and Isaacs, J. T.: Expression of transforming growth factor-β in the rat ventral prostate during castration induced programmed cell death. Mol. Endocrinol., 3: 1515, 1989.
18. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G. and Klocker, H.: Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392, 1996.
19. Lu, S., Tsai, S. Y. and Tsai, M. J.: Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4 and CKI p16 genes. Cancer Res., 57: 4511, 1997.
20. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M. and Pagano, M.: Increased proteasomore-dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med., 3: 231, 1997.
21. Kip-1 accumulation during the cell cycle. Science (Washington, DC), 271: 1861, 1996.
22. Chen, Y., Robles, A. I., Martinez, L. A., Liu, F., Gimenez-Conti, I. B. and Conti, C. J.: Expression of G1 cyclins, cyclin dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ., 7: 1571, 1998.
23. Kip-1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542, 1998.
24. Kip-1 cyclin-dependent kinase inhibitor presented by rappamycin. Nature, 372: 570, 1994.